Gaucher Leadership Spur’s lead program FLT201 for Gaucher disease type 1 is in Phase 1/2 with potential first in class status, creating attractive licensing or co development opportunities for partners looking to expand rare disease franchises with a proven gene therapy platform.

Neurodegeneration Opportunity The company is expanding toward Parkinson’s disease and other CNS conditions through GBA1 related candidates like SPR301, offering co development or milestone based collaborations with pharma focusing on neurology and precision gene therapies.

Data Momentum Ongoing data presentations at WORLDSymposium, ESGCT, IWGGD, and upcoming GALILEO 1/2 results provide credible evidence to engage investigator networks and pharma partners for sponsored trials, strategic alliances, and patient recruitment collaborations.

European Footprint UK base in Stevenage positions Spur for European regulatory strategy, regional trials, and partnerships with EU CROs, CMOs, and distribution networks that can accelerate market access and lifecycle management of gene therapies.

Manufacturing Readiness FLT201 and SPR301 programs imply need for scalable AAV manufacturing; partnerships with CMOs and supply chain experts could unlock scalable production, logistics, and commercialization readiness as programs advance.